Stock Details
AZN is AstraZeneca PLC's stock. Stock exchange NasdaqGS (Currency USD). Average price in 50 days is 65.67$. Average daily volumn in 3 months 7.47M. Market cap 205.18B



Stock symbol : AZN. Exchange : NasdaqGS. Currency : USD
Lastest price : 66.21$. Total volume : 7.17M. Market state POSTPOST
Click reload if you want to check the lastest price on market!!!

AstraZeneca PLC (AZN)
Last Price
66.21$
Change
1.67
Volume
7.17M

Previous Close64.54
Open65.48
Day Range64.98-66.36
Bid65.90 x 1.1k
Ask66.75 x 900
Volume7.17M
Average Volume7.47M
Market Cap205.18B
Beta0.12
52 Week Range53.63-71.70
Trailing P/EN/A
Foward P/E17.06
Dividend (Yield %)2.22%
Ex-Dividend Date2022-02-24



Financial Details


According to AstraZeneca PLC's financial reports the company's revenue in 2021 were 37.42B an increase( +42.31%) over the years 2020 revenue that were of 26.62B. In 2021 the company's total earnings were 112M while total earnings in 2020 were 3.2B(-96.27%).


Loading ...



Organization

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolis... m diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.

Market Cap:
205.18B
Revenue:
37.42B
Total Assets:
105.36B
Total Cash:
6.33B


News about "AstraZeneca PLC"

Analyst DZ Bank Price Target And Rating For AstraZeneca PLC (AZN)

Source from : stocksregister - 15 hours ago

AstraZeneca PLC (NASDAQ:AZN) at last check was buoying at $65.84 on Friday, May 20 with a rise of 2.01% from its closing price on previous day. Taking a look at stock we notice that its last check on ...See details»


DZ Bank slashes price target on AstraZeneca PLC [AZN] โ€“ find out why.

Source from : dbtnews - 3 days ago

AstraZeneca PLC closed the trading session at $65.64... AstraZeneca PLC [NASDAQ: AZN] closed the trading session at $65.64 on 05/17/22. The dayโ€™s price range saw the stock hit a low of $65.19, while ...See details»


astrazeneca-in-licenses-new-suite-of-covid-19-antibody-candidates-image

AstraZeneca In-Licenses New Suite Of COVID-19 Antibody Candidate(s)

Source from : YAHOO!Finance - 3 days ago

AstraZeneca plc (NASDAQ: AZN) moved to bolster its COVID-19 portfolio of antibodies with a $157 million licensing deal for experimental therapies developed by newly-launched UK-based biotech, RQ ...See details»


Investors have a limited window left to buy AstraZeneca PLC (AZN)

Source from : investchronicle - 3 days ago

AstraZeneca PLC (AZN) is priced at $65.65 after the most recent trading session. At the very opening of the session, the stock price was $63.35 and reached a high price of $64.795, prior to closing ...See details»


astrazeneca-azn-inks-deal-to-develop-covid-19-antibodies-image

AstraZeneca (AZN) Inks Deal to Develop COVID-19 Antibodies

Source from : Zacks.com on MSN.com - 2 days ago

AstraZeneca AZN announced that it has inked a licensing deal with London-based RQ Biotechnology (RQ Bio) for the latterโ€™s portfolio of early-stage monoclonal antibodies (mAbs), which target the ...See details»


astrazeneca-plc-nasdaqazn-expected-to-announce-earnings-of-078-per-share-image

AstraZeneca PLC (NASDAQ:AZN) Expected to Announce Earnings of $0.78 Per Share

Source from : Defense World - 11 days ago

Wall Street brokerages predict that AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) will announce $0.78 earnings per share for the current fiscal quarter, according to Zacks. Two analysts have provided ...See details»


AstraZeneca PLC (NASDAQ: AZN) Has Yet To Impress Analysts?

Source from : stocksregister - 3 days ago

AstraZeneca PLC (NASDAQ:AZN) traded at $65.64 at last check on Tuesday, May 17, made an upward move of 1.78% on its previous dayโ€™s price. Looking at the stock we see that its previous close was $64.49 ...See details»


astrazeneca-nasdaqazn-downgraded-by-kepler-capital-markets-image

AstraZeneca (NASDAQ:AZN) Downgraded by Kepler Capital Markets

Source from : ETF Daily News - 2 days ago

AstraZeneca Company Profile (Get Rating) AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its ...See details»


analysts-anticipate-astrazeneca-plc-nasdaqazn-to-post-078-eps-image

Analysts Anticipate AstraZeneca PLC (NASDAQ:AZN) to Post $0.78 EPS

Source from : Defense World - 11 days ago

Brokerages expect AstraZeneca PLC (NASDAQ:AZN โ€“ Get Rating) to post $0.78 earnings per share for the current fiscal quarter, according to Zacks Investment Research. Two analysts have issued estimates ...See details»


AstraZeneca PLC (AZN): Investors are paying attention to this stock

Source from : investchronicle - 10 days ago

For the readers interested in the stock health of AstraZeneca PLC (AZN). It is currently valued at $62.58. When the transactions were called off in the previous session, Stock hit the highs of $63.58, ...See details»


astrazeneca-plc-lonazn-shares-could-be-49-below-their-intrinsic-value-estimate-image

AstraZeneca PLC (LON:AZN) Shares Could Be 49% Below Their Intrinsic Value Estimate

Source from : YAHOO!Finance - 7 days ago

Does the May share price for AstraZeneca PLC ( LON:AZN ) reflect what it's really worth? Today, we will estimate ...See details»


rq-bio-talks-about-astrazeneca-deal-image

RQ Bio talks about AstraZeneca deal

Source from : Proactiveinvestors - 2 days ago

RQ Bio chief executive Hugo Fry joins Katie to talk about its deal with AstraZeneca PLC (LSE:AZN) (AZ) and its official launch.ย  The ...See details»


astrazeneca-covid-19-vaccine-wins-eu-nod-as-a-booster-shot-image

AstraZeneca COVID-19 vaccine wins EU nod as a booster shot

Source from : Seeking Alpha - 1 days ago

A panel of experts of the European Medicines Agency ((EMA)) has recommended the use of the COVID-19 vaccine developed by Anglo-Swedish drugmaker AstraZeneca (AZN) as a booster ...See details»


Heartbroken family of man take legal action after he died of blood clots two weeks after getting AstraZeneca jab

Source from : Hull Live on MSN.com - 2 days ago

The devastated family of man who died of blood clots weeks after getting the AstraZeneca jab are taking legal action. Jack Hurn received his first dose of the vaccine on May 29 last year. They had ...See details»